SEOUL-SEMICONDUCTOR
7.12.2021 11:02:11 CET | Business Wire | Press release
From a research study 30% of dentists will suffer from visual reduction capabilities in the next 30 years. For FARO, the solutions are already here.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005033/en/
With the new dentist lamp Eva and the new ceiling panel Siderea equipped with SunLike LED technology, the historical and global market leader in the orthodontist equipment sector FARO wants to keep demonstrating their technological leadership and implement the latest technology available that can improve the healthcare of the users.
FARO has developed 2 new products with edge technology that will improve patients and doctors' lives, as new products include solar spectrum light that will help on concentration, relax and recovery activities as demonstrated by recent studies done by University of Basel and Harvard medical school.
The Eva lamp, completely developed, tested and manufactured in FARO headquarters in Ornago, near Milan, represents a technological revolution in the market. After many years of research the reflector is perfectly adapted to the new LED technology obtaining the perfect system combination that brings the best possible light and beam angle to the needed place.
The version Eva Sunlight uses the special SunLike LEDs from Seoul Semiconductor with a solar spectrum at any colour temperature of the light and produces the closest light to the real and natural Sunlight.
With an illumination of 50.000 lux the Eva luminaire can guide the professionals to see all the smallest details in their day to day operations and guarantee at the same time the maximum visual comfort for the patient and the dentist.
Talking about technical parameters the new luminaire is achieving the greatest quality of the light with a CRI of 97 and a TM30 of 100 that brings a perfect vision and colour reproduction of the oral cavities.
To get immediate feedback on the lighting level in use, you just have to take a look at the headlamp; it is also possible to manage all the functions from smartphones and tablets using the app FARO Tech that is available in all app stores.
Finally, Eva has an integrated camera (Eva Cam) which allows you to photograph and video record footage in FHD or even 4K to broadcast live or share images later on.
Siderea Sunlight is the natural complement of the Eva lamp. With the Theia Tech – the special lamp that talks with the intensive light – reducing the stress of the pre-operation for patients.
This combination of Siderea and Eva forms the FARO light system that has been developed to guarantee the ideal conditions for developing the dentists' work.
Siderea is the only dentist panel in the market with technology SunLike that mimics the effects of the natural light with a uniform, multidirectional and proportional light and it deletes all the shadows from traditional lamps. Reassuring the wellbeing and visual effects to operate in the perfect ambient.
“To improve people lives: this is our inspiration as entrepreneurs” explains Cristina Cesari, General Manager of FARO that today counts more than 700 customers, with products installed in more than 70 countries around the world.
“To reproduce the natural light is our main research driver and is a challenge of great fascination. Today we can bring the benefits of Seoul Semiconductor SunLike technology into the health medical area and improve all professional environments” added Cristina Cesari.
Oliver Schaefer, Executive Vice-president for Seoul Semiconductor Europe said “We are very honoured and proud to be part of the new FARO products with our latest LED technology SunLike that brings the Sun benefits to indoor spaces”.
About FARO
FARO is an historic Italian brand for lighting in the dental sector. FARO stands for high Italian quality, creativity and innovation. We provide products and “lighting systems” to improve the “light experience” because light is not only seen, but above all life and well-being. We are an enthusiastic company serving demanding and visionary customers. In FARO we provide cutting-edge technologies that are considered industry benchmarks, we work enthusiastically to go beyond the boundaries of research to enable the next generation of professional lighting.
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike, WICOP, NanoDriver and nPola as examples.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005033/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom